Releases
China Approves Akeso’s Gumokimab for Plaque Psoriasis
China’s National Medical Products Administration has approved gumokimab, an anti-IL-17 monoclonal antibody developed by Akeso, for the treatment of moderate-to-severe plaque psoriasis. The regulatory nod follows clinical data showing the drug achieves superior skin clearance rates compared to existing therapeutic options while requiring a significantly reduced annual injection schedule.




















